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Several infection risk factors exist
simultaneously in this situation. In a
CL-endemic area, immigrant popula-
tions, who are mostly nonimmune,
exert pressure on the environment
(deforestation) that directly increases
their risk for exposure to infected vec-
tors, in the absence of prophylactic
measures. The initial short-term effect
of deforestation is the mobilization of
aggressive adult sandflies, which have
been disturbed while resting.
However, the ability of zoophilic vec-
tors to adapt to peridomestic environ-
ments has also already greatly influ-
enced the distribution of leishmanias-
es in South America (5–7).
Considering the uncertainty of the
population estimate, turnover, and
immunity status, we assume that inci-
dence rates should be considered cau-
tiously. Nevertheless, we found that
gold mining in forested areas consti-
tutes a risk factor for CL, at least in
French Guiana and probably in all
Amazonian rainforests. This risk
could be a public health concern.
Larger studies in other gold-mining
areas are required to quantify the inci-
dence of CL among workers to effec-
tively focus prophylactic and preven-
tive campaigns.
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To the Editor: The directly
observed treatment strategy (DOTS)
for tuberculosis (TB) treatment has
been implemented in Ghana since
1994. Before then, TB was treated
without adherence to any concerted
guidelines. The 2003 report of the
Ghanaian National Tuberculosis
Programme (NTP) stated a TB inci-
dence of 281/100,000 (1). NTP
ensures treatment of all patients with
an 8-month course of streptomycin,
isoniazid, rifampin, and pyrazinamide
(for 2 months), followed by thiaceta-
zone and isoniazid (6 months). The
cure rate for 2003 was >50% (1), and
>75% is anticipated for 2005.
To determine the extent of drug
resistance and to make suggestions
for future Ghanaian NTP strategies,
we assessed resistance against anti-
TB drugs used in Ghana. A total of
2,064 patients with new cases of pul-
monary TB were recruited at Korle
Bu Teaching Hospital, Accra; Komfo
Anokye Teaching Hospital, Kumasi;
15 periurban hospitals; and hospitals
in the Ashanti, Eastern, and Central
Regions of Ghana. These patients
were consecutively enrolled in a
cross-sectional study from September
2001 to December 2004. On all
patients’ clinical examinations, chest
radiographs, sputum smears for stain-
ing of acid-fast bacteria, HIV testing,
and culturing of Mycobacterium
tuberculosis complex strains were
performed. Samples were taken only
after informed consent was given. The
study was approved by the appropri-
ate ethics committees.
A total of 2,064 Mycobacterium
isolates were cultured at the Kumasi
Centre for Collaborative Research.
After decontamination of sputum sam-
ples (N-acetyl-L-cysteine/NaOH) and
centrifugation, sediments were trans-
ferred onto Lowenstein-Jensen (LJ)
media, incubated (37°C), and read
weekly for 10 weeks for mycobacteri-
al growth. Subsequently, cultures were
sent to the German National Reference
Centre for Mycobacteria in Borstel,
Germany, a reference laboratory of the
World Health Organization, for drug
sensitivity testing (DST; proportion
method on LJ media). Sensitivity to
isoniazid, rifampin, pyrazinamide,LETTERS
ethambutol, and streptomycin was
determined for 2,064 isolates and to
thiacetazone for 1,288 isolates. For
ambiguous results and DST of thiac-
etazone, the modified proportion
method (Bactec 460TB; Becton
Dickinson, Cockeys-ville, MD, USA)
was performed. Data were analyzed
with EpiInfo (Centers for Disease
Control and Prevention, Atlanta, GA,
USA) and Fourth Dimension (ACI
Group, San Jose, CA, USA) software
programs.
Of the isolates, 32.8% were from
female patients, and 67.8% were from
male patients. The mean age of partic-
ipants (33 years, range 10–60) did not
differ by sex. HIV prevalence was
14.3% (males, n = 179, females, n =
117).
A total of 1,578 (76.5%) isolates
were susceptible to all drugs tested,
whereas 304 (14.7%) were monodrug
resistant, and 177 (8.7%) were multi-
or polydrug resistant to combinations
(multidrug resistance meant resis-
tance to at least isoniazid and rifampin
(2.2%); polydrug resistance meant
resistance to several drugs, excluding
combined resistance to isoniazid and
rifampin (6.5%). The overall preva-
lence of any drug resistance was
23.5% (486 isolates) (Table). No dif-
ferences were observed between HIV-
negative and HIV-positive patients.
The highest level of resistance was
against streptomycin, followed by iso-
niazid. Resistance to rifampin, pyraz-
inamide, and thiacetazone was lower.
Monoresistance to ethambutol was
not observed; resistance to ethambu-
tol combined with other drugs
occurred in 0.9% of isolates.
In all, 6.5% of isolates were poly-
drug resistant and virtually always
included resistance to isoniazid.
Among isolates with double- and
triple drug resistance, combinations of
resistance to isoniazid and strepto-
mycin and to isoniazid-thiacetazone-
streptomycin occurred most frequent-
ly. Other combinations were relative-
ly rare.
In 1989, an initial drug resistance
rate of 54.5% in pulmonary TB was
observed in Ghana (2); 27% were
resistant to isoniazid, 23% to strepto-
mycin, 29% to thiacetazone, 16% to
streptomycin-isoniazid, and 5% to thi-
acetazone-streptomycin-isoniazid. A
later study reported a high prevalence
of primary drug resistance to isoniazid
(23%), while sensitivity to rifampicin,
pyrazinamide, ethambutol, strepto-
mycin, and ciprofloxacin was main-
tained (3). However, the number of
isolates tested was fewer in both stud-
ies (n = 99 and 25, respectively) than
in ours. This report supplements data
from patients in Ghana whose condi-
tions were newly diagnosed as HIV-
negative and HIV-positive. Samples
were collected in 2 large regions of
Ghana, the Greater Accra and the
Ashanti Regions, and were supple-
mented by samples from additional
regions. Thus, these results are likely
representative of the entire country.
The overall primary drug resist-
ance rate of 23.5% in Ghanaian TB
patients ranks Ghana among those
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African countries with a high preva-
lence of drug-resistant TB. The high
degree of mono-, multi- and polyre-
sistance to streptomycin may be the
result of selective pressure exerted by
treatment of other infections with
streptomycin and to incomplete treat-
ment courses. Drug resistance to
streptomycin and isoniazid are of con-
cern, since these drugs are core com-
ponents of the NTP. The relative inef-
fectiveness of streptomycin and the
low level of resistance to ethambutol
justify the most recent replacement of
streptomycin by ethambutol by the
Ghanaian NTP.
Low rates of initial drug resistance
have been reported in countries in
which the DOTS strategy has been
successfully implemented. Adequate
use of standardized treatment regi-
mens under DOTS will limit further
emergence of drug resistance but not
substantially reduce the current
degree of resistance (4). Although the
levels of drug resistance in Africa are
lower than in several other countries
(5), measures to provide controlled
application of second-line drugs,
supervision of drug distribution and
compliance, enforcement of DOTS
protocols, and sustained training of all
personnel involved in TB manage-
ment are crucial.
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To the Editor: Twenty-two human
cases of H5N1 highly pathogenic
avian influenza (HPAI) have been
reported in Thailand since 2003, with
14 deaths (1). From July to December
2005, I investigated Thai consumers’
food safety practices by conducting an
oral survey prepared in the Thai lan-
guage. Interviews were conducted in 3
areas that have not had cases of H5N1
avian influenza, Bangkok (urban, n =
126), Rangsit (suburban, n = 125), and
Phetchabun (rural, n = 50). Of the 301
Thai consumers surveyed, 92%
thought that Thailand has >1 food
safety problems, such as pesticide
residues (62%), poor personal hygiene
of food vendors (39%), and microbio-
logic/viral contamination of food
(26%). Although the Thai Ministry of
Public Health has conducted an
aggressive public education campaign
regarding HPAI (2), only 6% named
bird flu as their primary concern. Most
participants had some knowledge of
avian influenza; 88% of participants
knew the name of the disease, and of
those, all knew that infections can be
deadly, and 97% knew that interacting
with and slaughtering infected birds
are the most risky activities.
In the rural area, 72% of partici-
pants had backyard chickens (almost
no one had them in urban and subur-
ban areas). Of those, only 6% were
aware of the symptoms of HPAI in
poultry. Most villagers knew that min-
imizing contact with birds could
reduce their risk for infection; howev-
er, they were not sure how they could
minimize contact. None of the owners
of backyard chickens had tested them
for HPAI. The reporting system for
HPAI was not easily accessible for
home poultry producers.
The findings of this study are sim-
ilar to those of Olsen et al., who
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